Skip to main content
. 2022 Jul 1;10:90. doi: 10.1186/s40337-022-00615-9

Table 3.

Results from linear regression analysis with EDE-Q at two-year follow-up as outcome variable, for each baseline characteristic between ACT and TAU, while controlling for other characteristics

EDE-Q at T4 between ACT and TAU stratified by B (95% CI) SE p
AN spectrum − 0.856 (− 1.721 to .010) 0.423 .052
BN spectrum − 0.515 (− 1.526 to .496) 0.494 .306
Age < 25 at inclusion − 1.364 (− 2.268 to − .461) 0.440 .005
Age ≥ 25 at inclusion − 0.379 (− 1.371 to .612) 0.486 .441
Treatment duration < 12 months − 0.959 (− 1.833 to − .085) 0.431 .032
Treatment duration ≥ 12 months − 0.624 (− 1.628 to .381) 0.483 .211
MADRS-S < 20 − 0.884 (− 1.705 to − .063) 0.406 .036
MADRS-S ≥ 20 − 0.560 (− 1.904 to .784) 0.642 .394
EDE-Q T1 < 2.76 − 0.803 (− 1.804 to .197) 0.472 .108
EDE-Q T1 ≥ 2.76 − 0.612 (− 1.507 to .282) 0.443 .174

EDE-Q, eating disorder examination questionnaire; ACT, Acceptance and commitment therapy (set to 1); TAU, Treatment as usual (set to 0); Negative values in beta indicate lower ratings of EDE-QT4 for individuals in ACT